aztreonam 100 mg A medicine with azacitidine as the active component is administered through injection. Azacitidine is a nucleoside metabolic inhibitor used to treat several blood conditions, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Another name for it is a hypomethylating agent.
Myelodysplastic Syndromes (MDS): Low blood cell counts are a common symptom of a set of bone marrow illnesses known as MDS, which are characterised by inefficient synthesis of blood cells. Azacitidine is used to treat MDS patients who have failed prior treatments with other drugs or who have an intermediate or high risk of progressing to AML.
Azacitidine is also utilised for older AML patients who are not eligible for regular intense chemotherapy. This condition is known as acute myeloid leukaemia (AML). Overall survival and quality of life are improved.
Azacitidine causes hypomethylation and the consequent reactivation of tumour suppressor genes by integrating itself into the DNA of aberrant cells. This procedure aids in reducing the proliferation of aberrant cells and encouraging the production of more healthy blood cells.
Azadine (azacitidine) 100mg Injection adverse effects are possible and include low blood cell counts, low blood pressure, lethargy, nausea, vomiting, and diarrhoea. Patients using this medicine are closely watched, and depending on each patient's response and tolerability, the dosage and treatment plan are changed as necessary.
When using Azadine (azacitidine) 100mg Injection, patients must be under the supervision of a licenced healthcare provider with experience treating blood problems and administering chemotherapy. They can offer specific direction and assistance throughout the course of treatment.